Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Four‐food elimination diet with omeprazole vs omeprazole Endoscopic improvement at study endpoint (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination and amino acid formula vs four‐food elimination diet Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination and amino acid formula vs four‐food elimination diet Endoscopic improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Nebulized budesonide vs viscous budesonide Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Nebulized budesonide vs viscous budesonide Histological improvement at 8 weeks (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Nebulized budesonide vs viscous budesonide Endoscopic improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Viaskin milk patch vs placebo Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Viaskin milk patch vs placebo Histological improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Viaskin milk patch vs placebo Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cycled inhaled tobramycin (TNS) vs culture‐based TNS Eradication of P aeruginosa from the respiratory tract: proportion of participants with one or more isolates of P aeruginosa from the respiratory tract · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cycled inhaled tobramycin (TNS) vs culture‐based TNS FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Ciprofloxacin vs placebo added to cycled and culture‐based inhaled tobramycin (TNS) therapy Eradication of P aeruginosa from the respiratory tract: proportion of participants with one or more isolates of P aeruginosa from the respiratory tract · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Ciprofloxacin vs placebo added to cycled and culture‐based inhaled tobramycin (TNS) therapy FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin (TNS) FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin (TNS) Isolation of other micro‐organisms from the respiratory tract: number of positive cultures per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Inhaled colistin plus oral ciprofloxacin vs inhaled tobramycin (TNS) plus oral ciprofloxacin FEV1: relative change in % predicted FEV1 from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Inhaled colistin plus oral ciprofloxacin vs inhaled tobramycin (TNS) plus oral ciprofloxacin FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Inhaled colistin plus oral ciprofloxacin vs inhaled tobramycin (TNS) plus oral ciprofloxacin Growth and nutritional status · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Inhaled tobramycin (TNS) vs placebo Growth and nutritional status: change in weight (kg) from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of Pseudomonas aeruginosa from a… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Inhaled colistin plus oral ciprofloxacin vs inhaled tobramycin (TNS) plus oral ciprofloxacin Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Inhaled tobramycin (TNS) vs placebo Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of Pseudomonas aeruginosa from a… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral ciprofloxacin and inhaled colistin vs no treatment Eradication of P aeruginosa from the respiratory tract · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral ciprofloxacin and inhaled colistin vs no treatment FEV1 · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral ciprofloxacin and inhaled colistin vs no treatment FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral ciprofloxacin and inhaled colistin vs no treatment Growth and nutritional status · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral ciprofloxacin and inhaled colistin vs no treatment Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral ciprofloxacin and inhaled colistin vs no treatment Isolation of other micro‐organisms from the respiratory tract: number of positive cultures per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI FEV1 % predicted · children and adolescents with cystic fibrosis Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI FVC % predicted · children and adolescents with cystic fibrosis Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Inhaled tobramycin (TNS) vs placebo Isolation of other micro‐organisms from the respiratory tract: number of positive cultures per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of Pseudomonas aeruginosa from a… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI Growth and nutritional status · children and adolescents with cystic fibrosis Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI Frequency of infective pulmonary exacerbations · children and adolescents with cystic fibrosis Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI Isolation of other micro‐organisms from the respiratory tract · children and adolescents with cystic fibrosis Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI Adverse effects of antibiotics: number of participants reporting a serious adverse event · children and adolescents with cystic fibrosis Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intravenous ceftazidime with tobramycin vs oral ciprofloxacin Eradication of P aeruginosa from the respiratory tract: number of participants testing negative for P aeruginosa at 3 months and remaining free until 15 months · adults and children with cystic fibrosis and a positive microbiological isolate of Pseudomonas aeruginosa from a… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Inhaled tobramycin (TNS) (28 days) vs TNS (56 days) Eradication of P aeruginosa from the respiratory tract: time to next isolation of P aeruginosa from BAL, sputum or oropharyngeal cultures · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline with antibiotics (any dose or duration) vs pentoxifylline with antibiotics and immunoglobulin M‐enriched intravenous immunoglobulin Severe intraventricular haemorrhage · neonates with sepsis Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline with antibiotics (any dose or duration) vs pentoxifylline with antibiotics and immunoglobulin M‐enriched intravenous immunoglobulin Periventricular leukomalacia · neonates with sepsis Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline with antibiotics (any dose or duration) vs pentoxifylline with antibiotics and immunoglobulin M‐enriched intravenous immunoglobulin Length of hospital stay in days for survivors to discharge · neonates with sepsis Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline with antibiotics (any dose or duration) vs pentoxifylline with antibiotics and immunoglobulin M‐enriched intravenous immunoglobulin Retinopathy of prematurity, any stage · neonates with sepsis Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline with antibiotics (any dose or duration) vs immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics Chronic lung diseasein survivors · neonates with sepsis Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline with antibiotics (any dose or duration) vs immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics Severe intraventricular haemorrhage · neonates with sepsis Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline with antibiotics (any dose or duration) vs immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics Periventricular leukomalacia · neonates with sepsis Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline with antibiotics (any dose or duration) vs immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics Length of hospital stay in days for survivors to discharge · neonates with sepsis Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline with antibiotics (any dose or duration) vs immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics Retinopathy of prematurity, any stage · neonates with sepsis Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline with antibiotics (any dose or duration) vs pentoxifylline with antibiotics and immunoglobulin M‐enriched intravenous immunoglobulin Chronic lung disease in survivors · neonates with sepsis Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Surgery vs botulinum neurotoxin injections Presence and quality of binocularity at 6 months · children with infantile esotropia Interventions for infantile esotropia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Supplemental breast milk vs control Any adverse outcome · term newborns (≥ 37 completed weeks' postmenstrual age) and preterm infants (< 37 completed weeks' postmenstrual age)… Breastfeeding or breast milk for procedural pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Breastfeeding vs control Any adverse outcome · term newborns (≥ 37 completed weeks' postmenstrual age) and preterm infants (< 37 completed weeks' postmenstrual age)… Breastfeeding or breast milk for procedural pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Low glycaemic index (GI) or low glycaemic load (GL) diets vs any other diet All‐cause mortality · people with obesity or overweight Low glycaemic index or low glycaemic load diets for people with overweight or obesity (2023) · Cochrane | no estimate extracted | NR | No studies |